{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:40:23Z","timestamp":1790221223578,"version":"4.1.0"},"publisher-location":"Singapore","reference-count":61,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811072291","type":"print"},{"value":"9789811072307","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-981-10-7230-7_6","type":"book-chapter","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T10:29:29Z","timestamp":1528799369000},"page":"103-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Antiviral Drugs Against Alphaherpesvirus"],"prefix":"10.1007","author":[{"given":"Kimiyasu","family":"Shiraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","volume":"46","author":"JR Beadle","year":"2002","unstructured":"Beadle JR, Hartline C, Aldern KA et al (2002) Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 46:2381\u20132386","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4155\/fmc.13.192","volume":"6","author":"S Biswas","year":"2014","unstructured":"Biswas S, Sukla S, Field HJ (2014) Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections. Future Med Chem 6:45\u201355","journal-title":"Future Med Chem"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1086\/514011","volume":"176","author":"NJ Bodsworth","year":"1997","unstructured":"Bodsworth NJ, Boag F, Burdge D et al (1997) Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group. J Infect Dis 176:103\u2013111","journal-title":"J Infect Dis"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev.biochem.66.1.347","volume":"66","author":"PE Boehmer","year":"1997","unstructured":"Boehmer PE, Lehman IR (1997) Herpes simplex virus DNA replication. Annu Rev Biochem 66:347\u2013384","journal-title":"Annu Rev Biochem"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono K, Katsumata K, Kontani T et al (2010) ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 65:1733\u20131741","journal-title":"J Antimicrob Chemother"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","volume":"84","author":"K Chono","year":"2012","unstructured":"Chono K, Katsumata K, Kontani T et al (2012) Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir). Biochem Pharmacol 84:459\u2013467","journal-title":"Biochem Pharmacol"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","volume":"97","author":"K Chono","year":"2013","unstructured":"Chono K, Katsumata K, Suzuki H et al (2013) Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antivir Res 97:154\u2013160","journal-title":"Antivir Res"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0002-9343(82)90122-X","volume":"73","author":"DM Coen","year":"1982","unstructured":"Coen DM, Schaffer PA, Furman PA et al (1982) Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1. Am J Med 73:351\u2013360","journal-title":"Am J Med"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1073\/pnas.90.15.7376","volume":"90","author":"JI Cohen","year":"1993","unstructured":"Cohen JI, Seidel KE (1993) Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc Natl Acad Sci U S A 90:7376\u20137380","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nm0402-386","volume":"8","author":"JJ Crute","year":"2002","unstructured":"Crute JJ, Grygon CA, Hargrave KD et al (2002) Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 8:386\u2013391","journal-title":"Nat Med"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","volume":"36","author":"KC Cundy","year":"1999","unstructured":"Cundy KC (1999) Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36:127\u2013143","journal-title":"Clin Pharmacokinet"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jdermsci.2016.02.006","volume":"82","author":"T Daikoku","year":"2016","unstructured":"Daikoku T, Tannai H, Honda M et al (2016) Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy. J Dermatol Sci 82:160\u2013165","journal-title":"J Dermatol Sci"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","volume":"68","author":"E Clercq De","year":"2004","unstructured":"De Clercq E (2004) Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 68:2301\u20132315","journal-title":"Biochem Pharmacol"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/med.20011","volume":"25","author":"E Clercq De","year":"2005","unstructured":"De Clercq E (2005) (E)-5-(2-bromovinyl)-2\u2032-deoxyuridine (BVDU). Med Res Rev 25:1\u201320","journal-title":"Med Res Rev"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1128\/AAC.21.1.33","volume":"21","author":"E Clercq De","year":"1982","unstructured":"De Clercq E, Descamps J, Ogata M et al (1982) In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2\u2032-deoxyuridine and related compounds. Antimicrob Agents Chemother 21:33\u201338","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR16","unstructured":"Disease NIOaaI Herpes Drugs in Development (n.d.) In: Division of AIDS Anti-HIV\/OI\/TB Therapeutics Database"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1073\/pnas.90.9.4171","volume":"90","author":"JW Drake","year":"1993","unstructured":"Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90:4171\u20134175","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162199","volume":"11","author":"J Dunning","year":"2016","unstructured":"Dunning J, Kennedy SB, Antierens A et al (2016) Experimental treatment of Ebola virus disease with Brincidofovir. PLoS One 11:e0162199","journal-title":"PLoS One"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF02624593","volume":"25","author":"GB Elion","year":"1989","unstructured":"Elion GB (1989) Nobel lecture in physiology or medicine\u20141988. The purine path to chemotherapy. In Vitro Cell Dev Biol 25:321\u2013330","journal-title":"In Vitro Cell Dev Biol"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","volume":"74","author":"GB Elion","year":"1977","unstructured":"Elion GB, Furman PA, Fyfe JA et al (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 74:5716\u20135720","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.7326\/0003-4819-76-3-112-6-416","volume":"112","author":"JA Englund","year":"1990","unstructured":"Englund JA, Zimmerman ME, Swierkosz EM et al (1990) Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 112:416\u2013422","journal-title":"Ann Intern Med"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta Y, Takahashi K, Fukuda Y et al (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977\u2013981","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/095632020101200404","volume":"12","author":"M Honda","year":"2001","unstructured":"Honda M, Okuda T, Hasegawa T et al (2001) Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antivir Chem Chemother 12:233\u2013239","journal-title":"Antivir Chem Chemother"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0166-3542(98)00057-6","volume":"40","author":"M Ida","year":"1999","unstructured":"Ida M, Kageyama S, Sato H et al (1999) Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antivir Res 40:155\u2013166","journal-title":"Antivir Res"},{"key":"6_CR25","first-page":"703","volume":"161","author":"GG Jackson","year":"1963","unstructured":"Jackson GG, Muldoon RL, Akers LW (1963) Serological evidence for prevention of influenzal infection in volunteers by an anti-influenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemoter (Bethesda) 161:703\u2013707","journal-title":"Antimicrob Agents Chemoter (Bethesda)"},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.coviro.2014.06.003","volume":"8","author":"SH James","year":"2014","unstructured":"James SH, Prichard MN (2014) Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance. Curr Opin Virol 8:54\u201361","journal-title":"Curr Opin Virol"},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/cpt.3","volume":"97","author":"SH James","year":"2015","unstructured":"James SH, Larson KB, Acosta EP et al (2015) Helicase-primase as a target of new therapies for herpes simplex virus infections. Clin Pharmacol Ther 97:66\u201378","journal-title":"Clin Pharmacol Ther"},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1099\/0022-1317-82-11-2761","volume":"82","author":"T Kamiyama","year":"2001","unstructured":"Kamiyama T, Kurokawa M, Shiraki K (2001) Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 82:2761\u20132765","journal-title":"J Gen Virol"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1348-0421.1993.tb01719.x","volume":"37","author":"H Kawai","year":"1993","unstructured":"Kawai H, Yoshida I, Suzutani T (1993) Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus. Microbiol Immunol 37:877\u2013882","journal-title":"Microbiol Immunol"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0166-3542(81)90013-9","volume":"1","author":"ER Kern","year":"1981","unstructured":"Kern ER, Richards JT, Overall JC Jr et al (1981) A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. Antivir Res 1:225\u2013235","journal-title":"Antivir Res"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm0402-392","volume":"8","author":"G Kleymann","year":"2002","unstructured":"Kleymann G, Fischer R, Betz UA et al (2002) New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 8:392\u2013398","journal-title":"Nat Med"},{"issue":"3","key":"6_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","volume":"1","author":"P Koszalka","year":"2017","unstructured":"Koszalka P, Tilmanis D, Hurt AC (2017) Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 1(3):240\u2013246","journal-title":"Influenza Other Respir Viruses"},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1128\/AAC.29.5.894","volume":"29","author":"BA Larder","year":"1986","unstructured":"Larder BA, Darby G (1986) Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir. Antimicrob Agents Chemother 29:894\u2013898","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/358160a0","volume":"358","author":"E Littler","year":"1992","unstructured":"Littler E, Stuart AD, Chee MS (1992) Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160\u2013162","journal-title":"Nature"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1128\/AAC.21.2.358","volume":"21","author":"H Machida","year":"1982","unstructured":"Machida H, Kuninaka A, Yoshino H (1982) Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus. Antimicrob Agents Chemother 21:358\u2013361","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2004.10.002","volume":"65","author":"N Miwa","year":"2005","unstructured":"Miwa N, Kurosaki K, Yoshida Y et al (2005) Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus. Antivir Res 65:49\u201355","journal-title":"Antivir Res"},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jmv.10562","volume":"72","author":"T Okuda","year":"2004","unstructured":"Okuda T, Kurokawa M, Matsuo K et al (2004) Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. J Med Virol 72:112\u2013120","journal-title":"J Med Virol"},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/0005-2787(80)90234-8","volume":"609","author":"M Ostrander","year":"1980","unstructured":"Ostrander M, Cheng YC (1980) Properties of herpes simplex virus type 1 and type 2 DNA polymerase. Biochim Biophys Acta 609:232\u2013245","journal-title":"Biochim Biophys Acta"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/AAC.22.1.71","volume":"22","author":"DS Parris","year":"1982","unstructured":"Parris DS, Harrington JE (1982) Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother 22:71\u201377","journal-title":"Antimicrob Agents Chemother"},{"key":"6_CR40","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1099\/vir.0.19452-0","volume":"84","author":"M Patrone","year":"2003","unstructured":"Patrone M, Percivalle E, Secchi M et al (2003) The human cytomegalovirus UL45 gene product is a late, virion-associated protein and influences virus growth at low multiplicities of infection. J Gen Virol 84:3359\u20133370","journal-title":"J Gen Virol"},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/archinte.163.1.76","volume":"163","author":"M Reyes","year":"2003","unstructured":"Reyes M, Shaik NS, Graber JM et al (2003) Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 163:76\u201380","journal-title":"Arch Intern Med"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0","volume":"7","author":"S Safrin","year":"1997","unstructured":"Safrin S, Cherrington J, Jaffe HS (1997) Clinical uses of cidofovir. Rev Med Virol 7:145\u2013156","journal-title":"Rev Med Virol"},{"key":"6_CR43","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.71.5.3872-3878.1997","volume":"71","author":"JJ Sasadeusz","year":"1997","unstructured":"Sasadeusz JJ, Tufaro F, Safrin S et al (1997) Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J Virol 71:3872\u20133878","journal-title":"J Virol"},{"key":"6_CR44","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/0006-2952(84)90715-9","volume":"33","author":"PM Schwartz","year":"1984","unstructured":"Schwartz PM, Novack J, Shipman C Jr et al (1984) Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity. Biochem Pharmacol 33:2431\u20132438","journal-title":"Biochem Pharmacol"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/AAC.9.1.120","volume":"9","author":"C Shipman Jr","year":"1976","unstructured":"Shipman C Jr, Smith SH, Carlson RH et al (1976) Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in synchronized suspension cultures. Antimicrob Agents Chemother 9:120\u2013127","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"6_CR61","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1358\/dot.2017.53.11.2724803","volume":"53","author":"K. Shiraki","year":"2017","unstructured":"Shiraki K (2017) Helicase-primase inhibitor amenamevir for herpesvirus infection: towards practical application for treating herpes zoster. Drugs Today 53(11):573","journal-title":"Drugs of Today"},{"key":"6_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/095632029000100606","volume":"1","author":"K Shiraki","year":"1990","unstructured":"Shiraki K, Namazue J, Okuno T, Yamanishi K, Takahashi M (1990) Novel sensitivity of acyclovir-resistant varicella-zoster virus to anti-herpetic drugs. Antivir Chem Chemother 1:373\u2013375","journal-title":"Antivir Chem Chemother"},{"key":"6_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0166-3542(92)90039-8","volume":"18","author":"K Shiraki","year":"1992","unstructured":"Shiraki K, Ochiai H, Namazue J et\u00a0al (1992) Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus. Antivir Res 18:209\u2013214","journal-title":"Antivir Res"},{"key":"6_CR48","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1128\/JVI.72.9.6979-6987.1998","volume":"72","author":"FC Spector","year":"1998","unstructured":"Spector FC, Liang L, Giordano H et al (1998) Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol 72:6979\u20136987","journal-title":"J Virol"},{"key":"6_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcv.2004.04.002","volume":"32","author":"R Stranska","year":"2005","unstructured":"Stranska R, Schuurman R, Nienhuis E et al (2005) Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 32:7\u201318","journal-title":"J Clin Virol"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/358162a0","volume":"358","author":"V Sullivan","year":"1992","unstructured":"Sullivan V, Talarico CL, Stanat SC et al (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162\u2013164","journal-title":"Nature"},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.antiviral.2006.05.001","volume":"72","author":"M Suzuki","year":"2006","unstructured":"Suzuki M, Okuda T, Shiraki K (2006) Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antivir Res 72:157\u2013161","journal-title":"Antivir Res"},{"key":"6_CR52","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jis019","volume":"205","author":"S Tyring","year":"2012","unstructured":"Tyring S, Wald A, Zadeikis N et al (2012) ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis 205:1100\u20131110","journal-title":"J Infect Dis"},{"key":"6_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/09563202930040S601","volume":"4","author":"RA Vere Hodge","year":"1993","unstructured":"Vere Hodge RA, Cheng Y-C (1993) The mode of action of penciclovir. Antivir Chem Chemother 4:13\u201324","journal-title":"Antivir Chem Chemother"},{"key":"6_CR54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/363418a0","volume":"363","author":"M Itzstein Von","year":"1993","unstructured":"Von Itzstein M, Wu WY, Kok GB et al (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418\u2013423","journal-title":"Nature"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMoa1301150","volume":"370","author":"A Wald","year":"2014","unstructured":"Wald A, Corey L, Timmler B et al (2014) Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 370:201\u2013210","journal-title":"N Engl J Med"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1001\/jama.2016.18189","volume":"316","author":"A Wald","year":"2016","unstructured":"Wald A, Timmler B, Magaret A et al (2016) Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial. JAMA 316:2495\u20132503","journal-title":"JAMA"},{"key":"6_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0166-3542(03)00064-0","volume":"59","author":"Wassilew SW, Wutzler P, Brivddin Herpes Zoster Study G","year":"2003","unstructured":"Wassilew SW, Wutzler P, Brivddin Herpes Zoster Study G (2003) Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antivir Res 59:57\u201360","journal-title":"Antivir Res"},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJM198601163140303","volume":"314","author":"RJ Whitley","year":"1986","unstructured":"Whitley RJ, Alford CA, Hirsch MS et al (1986) Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314:144\u2013149","journal-title":"N Engl J Med"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2016.12.008","volume":"139","author":"M Yajima","year":"2017","unstructured":"Yajima M, Yamada H, Takemoto M et al (2017) Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor. Antivir Res 139:95\u2013101","journal-title":"Antivir Res"},{"key":"6_CR60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0026-895X(25)09197-7","volume":"36","author":"T Yokota","year":"1989","unstructured":"Yokota T, Konno K, Mori S et al (1989) Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Mol Pharmacol 36:312\u2013316","journal-title":"Mol Pharmacol"}],"container-title":["Advances in Experimental Medicine and Biology","Human Herpesviruses"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-10-7230-7_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:47:54Z","timestamp":1751683674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-10-7230-7_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9789811072291","9789811072307"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/978-981-10-7230-7_6","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}